Home | Medical Dictionary | Contact Us       
 
 
  • About
    Cedars-Sinai
  • Careers at
    Cedars-Sinai
  • Giving
    & Support
  • Health
    Conditions
  • Healthcare
    Professionals
  • Patients
    & Visitors
  • Programs
    & Services
  • Quality
    Measures
  • Research &
    Education
  • Research & Education
  • Academic Affairs
  • Burns & Allen Research Institute
  • Biomedical Sciences
  • Graduate Program
  • Curriculum Overview
  • Core Curriculum
  • Mentors & Teachers
  • Application Information
  • Research Cores
  • About Cedars-Sinai
  • Student Portal
  • Instructor Portal
  • Clinical Scholars Program
  • Institutes
  • Geri & Richard Brawerman Nursing Institute
  • Heart Institute
  • Medical Genetics Institute
  • Comprehensive Transplant Center
  • Neuroscience Institute
  • Samuel Oschin Comprehensive Cancer Institute
  • Women's Guild Pulmonary Disease Institute
  • Research Institutes
  • Board of Governors Gene Therapeutics Research Institute
  • Maxine Dunitz Neurosurgical Institute
  • Women's Cancer Research Institute
  • Services
  • Scientific Cores
  • Medical Library
  • To email this page please complete the form below and click "Send Page".
    Your Name:
    Your Email:
    Email To:
    Personal Message:
    (Optional)
 

Anjali Jain, PhD

Research Scientist, Hematology/Oncology

Email:anjali.jain@cshs.org
Phone:(310) 423-7376
Fax:(310) 423-7699

Institute Affiliation

Samuel Oschin Comprehensive Cancer Institute

Academic Appointments

Assistant Professor, Medicine

Research Focus

Response and resistance mechanisms of therapeutics targeting kinase signaling pathways in solid tumors utilizing prostate cancers as model systems. Molecular biology of hormone refractory prostate cancer progression with a focus on discovery and development of novel therapeutics.

Research Contributions

Discovery of EMP-1 as a biomarker of gefitinib resistance. Novel cross-talk mechanisms between EGFR and PPARg signaling networks.

Current investigations include:

Role of Epithelial to mesenchymal transitions in targeted therapy response. Monitoring therapeutic response with phosphoproteomics based signatures. Androgen receptor signaling.

Selected Publications

  1. Laux I, Jain A, Singh S, Agus DB: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer, 94(1): 85-92, 2006
  2. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB: Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int., 97(4): 691-7, 2006
  3. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc. Natl. Acad. Sci. U.S.A., 102(33): 11858-63, 2005
  4. Jain A, Agus DB: PPARgamma signaling: one size fits all?. Cell Cycle, 3(11): 1352-4, 2004
  5. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB: Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell, 5(6): 565-74, 2004
  6. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE: Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol. Endocrinol., 16(10): 2323-37, 2002
 
Cedars-Sinai Logo

© Copyright 2000-2007 Cedars-Sinai Health System.
All rights reserved.
Privacy Policy Terms and Conditions